Specific chromosomal translocations are associated with a number of hematologic malignancies. Several of these have been demonstrated to result in the activation of an oncogene. How an oncogene becomes activated by a translocation that does not affect its coding sequence is not known and is a central question in cancer research. This proposal will attempt to answer that question for the BCL-2 oncogene. In lymphomas with the t(14;18) translocation, the BCL-2 gene is translocated to the immunoglobulin locus. Because the immunoglobulin gene is active in B cells, a reasonable hypothesis is that the translocation somehow activates BCL-2, this is one step along the way to development of the malignant phenotype. The applicant proposes to study the mechanism of activation at a molecular level in human lymphoma tissue. The activation of the translocated BCL-2 gene will be compared to the transcriptional regulation of the normal BCL-2 gene during B-cell development and during B-cell activation. The goal is to reach a better understanding of the mechanisms of malignant transformation.
The specific aims are: A) determination of the role of CREB in the regulation of BCL-2 in normal B cells; B) determination of the role of other transcription factors in modifying the activity of CREB on the BCL-2 promoter in normal B cells; C) determination of the role of CREB, WT1, pi1, p53, the URE factor, Myb and the immunoglobulin enhancers in the deregulation of the translocated BCL-2 gene in t(14;18) lymphomas; D) creation of a model system of the t(14;18) translocation to test the hypotheses for the deregulation of BCL-2. The successful completion of this proposal will represent the first instance where the molecular mechanisms involved in the transcriptional activation of an oncogene by translocation are known. The transcription factors that are required for the activation of expression of BCL-2 will be identified, and the region of the immunoglobulin locus that are responsible for this will be characterized.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA056764-08
Application #
6350110
Study Section
Special Emphasis Panel (ZRG2-MEP (01))
Project Start
1993-08-01
Project End
2002-06-30
Budget Start
2001-02-01
Budget End
2002-06-30
Support Year
8
Fiscal Year
2001
Total Cost
$230,166
Indirect Cost
Name
Stanford University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
800771545
City
Stanford
State
CA
Country
United States
Zip Code
94305
Xiang, H; Noonan, E J; Wang, J et al. (2011) The immunoglobulin heavy chain gene 3' enhancers induce Bcl2 deregulation and lymphomagenesis in murine B cells. Leukemia 25:1484-93
Duan, H; Heckman, C A; Boxer, L M (2007) The immunoglobulin heavy-chain gene 3'enhancers deregulate bcl-2 promoter usage in t(14;18) lymphoma cells. Oncogene 26:2635-41
Xiang, Hong; Wang, Jinghong; Boxer, Linda M (2006) Role of the cyclic AMP response element in the bcl-2 promoter in the regulation of endogenous Bcl-2 expression and apoptosis in murine B cells. Mol Cell Biol 26:8599-606
Heckman, Caroline A; Wheeler, Melissa A; Boxer, Linda M (2003) Regulation of Bcl-2 expression by C/EBP in t(14;18) lymphoma cells. Oncogene 22:7891-9
Heckman, Caroline A; Cao, Thai; Somsouk, Lina et al. (2003) Critical elements of the immunoglobulin heavy chain gene enhancers for deregulated expression of bcl-2. Cancer Res 63:6666-73
Zheng, Z; Venkatapathy, S; Rao, G et al. (2002) Expression profiling of B cell chronic lymphocytic leukemia suggests deficient CD1-mediated immunity, polarized cytokine response, altered adhesion and increased intracellular protein transport and processing of leukemic cells. Leukemia 16:2429-37
Heckman, Caroline A; Mehew, John W; Boxer, Linda M (2002) NF-kappaB activates Bcl-2 expression in t(14;18) lymphoma cells. Oncogene 21:3898-908
Arcinas, M; Heckman, C A; Mehew, J W et al. (2001) Molecular mechanisms of transcriptional control of bcl-2 and c-myc in follicular and transformed lymphoma. Cancer Res 61:5202-6
Wu , Y; Mehew, J W; Heckman, C A et al. (2001) Negative regulation of bcl-2 expression by p53 in hematopoietic cells. Oncogene 20:240-51
Heckman, C A; Mehew, J W; Ying, G G et al. (2000) A-Myb up-regulates Bcl-2 through a Cdx binding site in t(14;18) lymphoma cells. J Biol Chem 275:6499-508

Showing the most recent 10 out of 17 publications